Aprepitant, a substance P/neurokinin-1 (NK₁) receptor antagonist, has become an indispensable therapeutic agent in oncology care. As the first drug in its class approved for the prevention of chemotherapy-induced nausea and vomiting (CINV), Aprepitant has generated substantial global demand across pharmaceutical supply chains. For manufacturers, distributors, and procurement professionals, understanding the landscape of Aprepitant buyers is essential for market penetration and supply chain optimization. This comprehensive guide presents a detailed Aprepitant global buyers list, market analysis, and strategic insights for stakeholders across the pharmaceutical industry. Understanding the Aprepitant Market Landscape The global Aprepitant market has experienced significant growth, driven by rising cancer incidence rates and increasing awareness of CINV management.…